Company Analysis Pacific Shuanglin Bio-pharmacy Co., LTD
1. Summary
Advantages
- Price (21.83 Β₯) is less than fair price (25.39 Β₯)
- The stock's return over the last year (23.19%) is higher than the sector average (-36.11%).
- Current debt level 0% is below 100% and has decreased over 5 years from 14.34%.
Disadvantages
- Dividends (0%) are below the sector average (1.83%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=11.95%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Pacific Shuanglin Bio-pharmacy Co., LTD | Healthcare | Index | |
|---|---|---|---|
| 7 days | -9.4% | -4.6% | 3.1% |
| 90 days | -24.3% | -16% | 11.9% |
| 1 year | 23.2% | -36.1% | 15.9% |
000403 vs Sector: Pacific Shuanglin Bio-pharmacy Co., LTD has outperformed the "Healthcare" sector by 59.3% over the past year.
000403 vs Market: Pacific Shuanglin Bio-pharmacy Co., LTD has outperformed the market by 7.33% over the past year.
Stable price: 000403 is not significantly more volatile than the rest of the market on "Shenzhen Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 000403 with weekly volatility of 0.446% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (21.83 Β₯) is lower than the fair price (25.39 Β₯).
Price not significantly lower than the fair price: The current price (21.83 Β₯) is slightly lower than the fair price by 16.3%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (69.4).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (63.57).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is lower than that of the sector as a whole (3.96).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (3.79).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (6.51).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (5.87).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (11.85).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (25.54).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20% over the last 5 years.
Earnings Slowdown: The last year's return (-100%) is below the 5-year average return (-20%).
Profitability vs Sector: The return for the last year (-100%) is lower than the return for the sector (13.28%).
5.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (11.95%).
ROE vs Market: The company's ROE (0%) is lower than that of the market as a whole (9.38%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (5.4%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (3.95%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.83%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.83.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
